1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
Hakimeh Ebrahimi-Nik, Christina K Baumgartner, Arvin Iracheta-Vellve, Keith M Hamel, Kira Olander, Thomas GR Davis, Kathleen A McGuire, Geoff T Halvorsen, Omar I Avila, Chirag Patel, Sarah Kim, Ashwin V Kammula, Audrey J Muscato, Kyle Halliwill, Prasanthi Geda, Kelly Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D Yeary, James C Patti, Tyler M Balon, Rebecca Mathew, Carey Backus, Domenick Kennedy, Angeline Chen, Kenton Longenecker, Joseph Klahn, Cara Hrusch, Navasona Krishnan, Charles W Hutchins, Jacqueline Aguado, Marinka Bulic, Payal Tiwari, Kayla J Colvin, Cun Lan Chuong, Ian C Kohnle, Matthew G Rees, Andrew Boghossian, Melissa Ronan, Jennifer A Roth, Meng-Ju Wu, Debattama R Sen, Gabriel K Griffin, Nabeel El-Bardeesy, Patricia Trusk, Meng Sun, Yue Liu, Joshua H Decker, Yi Yang, Stacey Fossey, Wei Qiu, Qi Sun, Marcia N Paddock, Elliot P Farney, Clay Beauregard, Jennifer M Frost, Kathleen B Yates, Philip R Kym, Robert T Manguso
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1850; DOI: 10.1136/jitc-2023-SITC2023.1403-A
